Gila Therapeutics is a startup based in All, most recent round Series A, 1 tracked investor.
Based in All, Gila Therapeutics is a startup. Its most recent tracked round is Series A. Brouky records 1 investor associated with the company.
Gila Therapeutics is a clinical-stage biotech developing a first-of-its-kind Topical Lingual Signaling platform (micro-dose PYY & GLP-1 melts on the tongue) to target brain regions that regulate food intake and metabolism for the treatment of obesity, type 2 diabetes, and cardiometabolic disorders, with no expected systemic exposure and a favorable Phase I safety profile.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.